Inhibition of miR-21* by pharmacological inhibitor ameliorated the cardiac hypertrophy induced by Ang II, suggesting fibroblast-derived miR-21* as a potential therapeutic target in cardiac hypertrophy [62]. The gene discussed is AGT; the disease is cardiac hypertrophy.